Calcium Folinate Treatment of Spastic Paraplegia 56

Summary

SPG56 is one of the complicated and early-onset HSP subtypes caused by genetic mutations in CYP2U1. So far, there is no standardized and specific clinical therapy for SPG56. The goal of this clinical trial is to explore the efficacy and safety of calcium folinate in the treatment of SPG56 patients. This study is prospective, open-label and single arm and this trial will last for 6 years. A total of 10 patients will participate and they will receive calcium folinate treatment and professional clinical evaluation regularly.

Timeline

Start

2024-07-01

Primary completion

2030-05-31

Completion

2030-05-31

Drugs

Indications